These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases. Tremblay L; Pineton de Chambrun G; De Vroey B; Lavogiez C; Delaporte E; Colombel JF; Cortot A J Crohns Colitis; 2011 Oct; 5(5):457-60. PubMed ID: 21939920 [TBL] [Abstract][Full Text] [Related]
6. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941 [TBL] [Abstract][Full Text] [Related]
8. Toxic epidermal necrolysis, agranulocytosis and erythroid hypoplasia associated with sulphasalazine. Maddocks JL; Slater DN J R Soc Med; 1980 Aug; 73(8):587-8. PubMed ID: 6112274 [No Abstract] [Full Text] [Related]
9. Toxic Epidermal Necrolysis in a Pediatric Patient. Hagen S; Grey K; Hylwa S Minn Med; 2016; 99(3):49-50. PubMed ID: 27323526 [No Abstract] [Full Text] [Related]
10. Sulfasalazine-Induced Toxic Epidermal Necrolysis: A Challenging Case During the COVID-19 Pandemic. Shahidi-Dadras M; Shahrigharahkoshan S; Yazdi E; Fatemi A; Mahboubi-Fooladi Z; Dadkhahfar S Adv Emerg Nurs J; 2021 Jul-Sep 01; 43(3):194-197. PubMed ID: 34397495 [TBL] [Abstract][Full Text] [Related]
11. Erythroderma and toxic epidermal necrolysis caused by to 5-aminosalacylic acid. Iemoli E; Piconi S; Ardizzone S; Bianchi Porro G; Raimond F Inflamm Bowel Dis; 2006 Oct; 12(10):1007-8. PubMed ID: 17012974 [No Abstract] [Full Text] [Related]
12. Stevens-Johnson syndrome and toxic epidermal necrolysis. Eginli A; Shah K; Watkins C; Krishnaswamy G Ann Allergy Asthma Immunol; 2017 Feb; 118(2):143-147. PubMed ID: 28153080 [No Abstract] [Full Text] [Related]
13. [Pathogenesis and treatment of toxic epidermal necrolysis]. Hensen E Tijdschr Ziekenverpl; 1981 Jun; 34(13):563-7. PubMed ID: 6115482 [No Abstract] [Full Text] [Related]
14. Stevens-Johnson syndrome and toxic epidermal necrolysis at the University Hospital of the West Indies, Jamaica. East-Innis AD; Thompson DS West Indian Med J; 2013 Sep; 62(7):589-92. PubMed ID: 24831894 [TBL] [Abstract][Full Text] [Related]
15. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Abe R; Shimizu T; Shibaki A; Nakamura H; Watanabe H; Shimizu H Am J Pathol; 2003 May; 162(5):1515-20. PubMed ID: 12707034 [TBL] [Abstract][Full Text] [Related]
16. Epidermal necrolysis and autoimmune diseases: two more observations supporting the concept that 'toxic' epidermal necrolysis can be 'non-toxic'. Dumas M; Hua C; Hotz C; Velter C; Duong TA; Maraffi T; Ortonne N; Hüe S; Fardet L; de Prost N; Wolkenstein P; Ingen-Housz-Oro S; Chosidow O J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):e360-e361. PubMed ID: 29524279 [No Abstract] [Full Text] [Related]
17. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Letko E; Papaliodis DN; Papaliodis GN; Daoud YJ; Ahmed AR; Foster CS Ann Allergy Asthma Immunol; 2005 Apr; 94(4):419-36; quiz 436-8, 456. PubMed ID: 15875523 [TBL] [Abstract][Full Text] [Related]
18. Clues to pathogenesis of toxic epidermal necrolysis. Merot Y; Saurat JH Int J Dermatol; 1985 Apr; 24(3):165-8. PubMed ID: 3888879 [No Abstract] [Full Text] [Related]